← United States · Coverage record
US · SEC FORM 4
Klotho Neurosciences, Inc.
KLTO · Nasdaq · CIK 0001907223 · Healthcare
INSIDER SIGNAL
4 qualifying P purchase groups
in the current 180-day scoring window
6 Form 4 transaction lines observed in the same window
2 sales · 0 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
—
Purchase breadth & concentration
Roles in the peak window: Chief Financial Officer, Director. Concentration uses priced qualifying P lines only and does not change the saved score.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-08-25 · LeBlanc Jeff.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
The FINRA report lists no short interest for this ticker.
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-08-25 | LeBlanc Jeff | Purchase (P) | Common Stock | 14,000 | USD 9.72 | USD 136,080 | SEC filing ↗ |
| 2026-07-22 | Sawyer Jason David | Purchase (P) | Common Stock | 240,000 | USD 0.23 | USD 55,200 | SEC filing ↗ |
| 2026-07-20 | McGarity Jon | Purchase (P) | Common Stock | 140,000 | USD 0.18 | USD 25,200 | SEC filing ↗ |
| 2026-07-16 | LeBlanc Jeff | Purchase (P) | Common Stock | 1,400,000 | USD 0.18 | USD 252,000 | SEC filing ↗ |
| 2022-04-07 | Redwoods Capital LLC | Purchase (P) | Common Stock | 37,500 | USD 10.00 | USD 375,000 | SEC filing ↗ |
| 2022-04-04 | Redwoods Capital LLC | Purchase (P) | Common Stock | 377,500 | USD 10.00 | USD 3,775,000 | SEC filing ↗ |
Form 4 evidence
12 transaction lines in the latest 365-day window; 25 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | El-Dada Riad Hussein | Sale (S) | Common Stock | 3,500 | USD 9.35 | USD 32,727 | SEC filing ↗ |
| 2026-08-25 | LeBlanc Jeff | Purchase (P) | Common Stock | 14,000 | USD 9.72 | USD 136,080 | SEC filing ↗ |
| 2026-07-22 | Sawyer Jason David | Purchase (P) | Common Stock | 240,000 | USD 0.23 | USD 55,200 | SEC filing ↗ |
Show recent Form 4 evidence (12 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | El-Dada Riad Hussein | Sale (S) | Common Stock | 3,500 | USD 9.35 | USD 32,727 | SEC filing ↗ |
| 2026-08-25 | LeBlanc Jeff | Purchase (P) | Common Stock | 14,000 | USD 9.72 | USD 136,080 | SEC filing ↗ |
| 2026-07-22 | Sawyer Jason David | Purchase (P) | Common Stock | 240,000 | USD 0.23 | USD 55,200 | SEC filing ↗ |
| 2026-07-20 | McGarity Jon | Purchase (P) | Common Stock | 140,000 | USD 0.18 | USD 25,200 | SEC filing ↗ |
| 2026-07-16 | LeBlanc Jeff | Purchase (P) | Common Stock | 1,400,000 | USD 0.18 | USD 252,000 | SEC filing ↗ |
| 2026-06-25 | El-Dada Riad Hussein | Sale (S) | Common Stock | 175,000 | USD 0.23 | USD 40,250 | SEC filing ↗ |
| 2026-03-04 | ZENTMAN SAMUEL M | Award / grant (A) | Common Stock | 350,000 | USD — | USD — | SEC filing ↗ |
| 2026-03-04 | SINKULE JOSEPH | Award / grant (A) | Common Stock | 2,500,000 | USD — | USD — | SEC filing ↗ |
| 2026-03-04 | McGarity Jon | Award / grant (A) | Common Stock | 350,000 | USD — | USD — | SEC filing ↗ |
| 2026-03-04 | LeBlanc Jeff | Award / grant (A) | Common Stock | 2,500,000 | USD — | USD — | SEC filing ↗ |
| 2026-03-04 | Hirschman Shalom | Award / grant (A) | Common Stock | 350,000 | USD — | USD — | SEC filing ↗ |
| 2026-03-04 | El-Dada Riad Hussein | Award / grant (A) | Common Stock | 350,000 | USD — | USD — | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | KLTO |
| CIK | 0001907223 |
| Sector | Healthcare |
| Industry | — Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 25 transaction lines from 2022-04-04 to 2026-10-01 6 P purchase lines · 5 S sale lines · 14 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.